AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 OCT 8 - (NewsRx.com & NewsRx.net) -- Aphios Corporation has been awarded a phase I Small Business Innovative Research (SBIR) grant for the "Development of Novel Anti-Smallpox Therapeutics from Marine Microorganisms," from the National Center for Complementary and Alternative Medicine (NCCAM) of the U.S. National Institutes of Health (NIH).
Smallpox infection is characterized by a high fever and rash; the mortality rate is very high, approximately 30%. Person to person infection usually occurs by the transfer of aerosols or fluid droplets. The vast vaccination effort between 1967 and 1972 led to the worldwide eradication of Smallpox in 1977.
Currently, viral stocks of Smallpox are restricted to the Centers for Disease Control in Atlanta, Georgia and the State Research Center of Virology and Biotechnology in Novosibirsk, Russia; reputedly, Smallpox may be available on the black market to anyone with the correct price. The terrorist events of September 11th, 2001 and subsequent criminal anthrax exposures have increased the awareness of Smallpox's use as a biological weapon, and steps are being taken to prepare for the possibility of an attack. Smallpox is considered a "Category A priority pathogen" by the NIH and Department of Homeland Security (DHS).
While the U.S. has sufficient vaccines on hand to vaccinate the entire population, there are concerns about the logistical implementation of such a plan and the timing between exposure and efficacy. There are also concerns ...
Source: HighBeam Research, SBIR grant awarded to develop anti-smallpox therapeutics.